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ABSTRACT
Genomic DNA (gDNA) contamination is an inherent
problem during RNA purification that can lead to
non-specific amplification and aberrant results in
reverse transcription quantitative PCR (RT—qPCR).
Currently, there is no alternative to RT( ) controls to
evaluate the impact of the gDNA background on
RT–PCR data. We propose a novel method
(ValidPrime) that is more accurate than traditional
RT( ) controls to test qPCR assays with respect to
their sensitivity toward gDNA. ValidPrime measures
the gDNA contribution using an optimized
gDNA-specific ValidPrime assay (VPA) and gDNA
reference sample(s). The VPA, targeting a non-
transcribed locus, is used to measure the gDNA
contents in RT(+) samples and the gDNA reference
is used to normalize for GOI-specific differences in
gDNA sensitivity. We demonstrate that the
RNA-derived component of the signal can be accur-
ately estimated and deduced from the total signal.
ValidPrime corrects with high precision for both
exogenous (spiked) and endogenous gDNA,
contributing  60% of the total signal, whereas sub-
stantially reducing the number of required qPCR
control reactions. In conclusion, ValidPrime offers
a cost-efficient alternative to RT( ) controls and
accurately corrects for signals derived from gDNA
in RT–qPCR.
INTRODUCTION
Accurate gene expression analysis by reverse transcription
(RT) quantitative PCR (qPCR) requires assays with high
speciﬁcity for the target cDNA/reference gene, collectively
referred to herein as the Gene-Of-Interest (GOI). It is
important to have negligible signal contribution from
experimental artifacts, such as primer–dimers and
contaminating genomic DNA (gDNA). Traditionally,
primer–dimer formation is tested using a ‘no template
control’ (NTC) and gDNA contamination levels are
measured with RT( ) controls [which differ from
regular RT(+) reactions in that no reverse transcriptase
is added]. Contamination of gDNA is an inherent
problem during RNA puriﬁcation due to the similar
physicochemical properties of RNA and DNA. Since
gDNA contamination levels are frequently not uniform
between samples (1) and the sensitivity toward gDNA
differs greatly between GOI assays, RT( ) controls are
needed for each sample/assay pair, which substantially
adds to the cost and labor in RT–qPCR proﬁling
studies. A difference of at least ﬁve quantiﬁcation cycles
(Cq) between RT(+) and RT( ) reactions indicates that
<3% of the total signal originates from gDNA, and is
commonly used as limit to ensure accurate estimation of
GOI expression. Smaller differences typically call for
DNase treatment of samples.
The accuracy of gDNA background estimation, as
measured with RT( ) reactions, is compromised due to
the fact that GOI assays, designed to amplify target tran-
scripts, are used even though they are not optimized for
gDNA ampliﬁcation. Furthermore, intrinsic characteris-
tics of RT( )–qPCRs that inﬂuence the result of the cor-
rection, such as ampliﬁcation efﬁciencies, are difﬁcult to
assess. In addition, as proposed theoretically (2) and
shown experimentally (3,4), a low initial number of
target molecules leads to a large variability between repli-
cates, mainly due to stochastic effects. All together, this
explains the low reproducibility frequently observed in
RT( ) reactions.
The qPCR assays can be either gDNA sensitive or
insensitive. Whereas qPCR assays can be designed to be
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ﬂanking a long intron or with primers that cross exon–
exon junctions, qPCR assays for single-exon genes will
readily amplify contaminating gDNA. The gDNA back-
ground signal is even further ampliﬁed in the presence of
multiple genomic copies or pseudogenes. The latter are
particularly troublesome since they may originate from
retrotransposons without introns that are ampliﬁed even
with intron-spanning assays. Thus, there exists both vari-
ation in the degree of contamination between samples and
large differences between assays in terms of their sensitiv-
ity to gDNA. Therefore, general methods of controlling
and correcting for gDNA contamination are essential for
accurate measurements of gene expression.
As an alternative to RT( ) reactions, we have
developed a procedure that determines the impact of the
gDNA contamination on the measured signal much more
accurately and allows validation of qPCR primers with
respect to their sensitivity toward gDNA. We show in
proof-of-principle experiments that efﬁcient background
correction can be performed with gDNA contamination
representing  60% of the total signal.
MATERIALS AND METHODS
Samples
All samples were from mouse (C57Bl/6J) tissues (kidney,
liver, adipose tissue, uterus, peritoneal macrophages). All
experimental procedures involving animals were per-
formed in accordance with the principles and guidelines
established by the National Institute of Medical Research
(Inserm) and were approved by the local Animal Care and
Use Committee. Prior to sampling, mice were anesthetized
by intraperitoneal injection of ketamine (100mgkg
 1) and
xylazine (10mgkg
 1). Tissues were snap-frozen in liquid
nitrogen and stored at  80 C. Isolation of peritoneal
macrophages has been described elsewhere (5).
Macrophages were in some cases treated with 20ng/ml
LPS ex vivo for 4h prior to RNA extraction.
DNA extraction
C57Bl/6J mouse gDNA was extracted from whole blood
using the PerfectPure DNA Blood Cell Kit, according to
the recommended protocol (50PRIME GmbH, Hamburg,
Germany). Good results were also obtained with gDNA
puriﬁed from mouse tails by phenol/chloroform extraction
after Proteinase K digestion (6). The DNA concentration
was determined spectroscopically (NanoDrop).
RNA extraction
Total RNA was extracted using a double puriﬁcation
protocol. Brieﬂy, Trireagent (Sigma-Aldrich, St Louis,
MI, USA) was added to the frozen tissue sample, which
was homogenized in a Precellys 24 homogenizer (Bertin
Technologies, France). After the extraction step, the
supernatant was gently mixed with 1 Vol 70% ethanol
and applied on a total RNA miniprep Genelute column,
where it was washed and eluted following the instructions
from the manufacturer (Sigma-Aldrich). The integrity and
quality of the RNA was tested by capillary micro-
electrophoresis [MultiNA (Shimadzu) or Experion
(BioRad)] and spectroscopically (NanoDrop). A fraction
of the RNA was DNase treated using the DNAfree kit
from Ambion. To avoid inhibition of the reverse tran-
scriptase, the volume of DNAse treated RNA did not
exceed 25% of the total volume during RT.
RT
Total RNA (1.0–5.0mg) was reverse transcribed in
20–50ml using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) using random
hexamers. The reaction mixture was incubated for
10min at 25 C, 120min at 37 C and ﬁnally for 5min at
85 C, according to instructions from the manufacturer
(Applied Biosystems). RT reactions were diluted
5–10-fold prior to qPCR.
Real-time qPCR
Conventional qPCR. All reactions (except when indicated)
were performed in duplicate 10ml volumes using 20ng
reverse transcribed total RNA in a StepOnePlus
system (Applied Biosystems) with the SsoFast EvaGreen
Supermix (BioRad) and an assay concentration of 300nM
using the cycling parameters: 95 C (20s) followed by 40
cycles at 95 C (3s) and 60 C (20s). Melting curve analysis:
95 C (15s); 60 C (60s) and a progressive increase up to
95 C (0.5 C/min). Analysis of the data was performed
with the StepOne software v.2.2.
High-throughput qPCR. The 96.96 Dynamic Arrays for
the microﬂuidic BioMark
TM system (Fluidigm
Corporation, CA, USA) (7) were used to study gene ex-
pression in 6.5ng cDNA from mouse peritoneal macro-
phages or mouse uterus, as described below.
Speciﬁc target ampliﬁcation. Pre-ampliﬁcation of cDNA
(produced from 25 to 65ng of total RNA) was performed
in the StepOnePlus cycler (Applied Biosystems) [at 95 C
for 10 min activation step followed by 14 cycles: 95 C,
(15s), 60 C, (4min)] in a total volume of 5mli nt h e
presence of all primers at a concentration of 50nM.
After pre-ampliﬁcation, 20ml Low EDTA TE Buffer [10
mM Tris pH8 (Ambion), 0.1mM EDTA pH8 (Sigma)]
was added to each sample.
Sample Mix for BioMark analysis. The pre-sample mix
contained 66.7% 2X Taqman Gene Expression Master
Mix (Applied Biosystems), 6.67% 20X DNA Binding Dye
Sample Loading Reagent (Fluidigm), 6.67% 20X
EvaGreen
TM (Biotium), 20% Low EDTA TE Buffer.
Sample mix was obtained by mixing 5.6ml of the
pre-sample mix with 1.9ml of diluted cDNA.
Assay Mix. A quantity of 3.8ml 2X Assay Loading
Reagent (Fluidigm) and 1.9ml Low EDTA TE Buffer
were mixed with 1.9ml of primers (20mM of each
forward and reverse primer).
qPCR conditions. After priming of the 96.96 Dynamic
Array in the NanoFlex
TM 4-Integrated Fluidic Circuits
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of each assay mix were added to dedicated wells. The
dynamic array was then placed again in the IFC
Controller for loading and mixing under the following
conditions: 50 C (2min); 70 C (30min) and 25 C
(10min). The loaded Dynamic Array was transferred to
the BioMark
TM real-time PCR instrument. After initial
incubation at 50 C (2min) and activation of the
Hotstart enzyme at 95 C (10min) cycling was performed
using 95 C (15s), and 60 C (1min) for 35 cycles, followed
by melting curve analysis (1 C/3s).
Data analysis. Initial data analysis was performed with
the Fluidigm real-time PCR analysis software v. 3.0.2
with linear derivative baseline correction and a quality
correction set to 0.65.
Design of ValidPrime assays
Intergenic regions in the mouse genome with no known
transcriptional activity were selected using the UCSC
genome browser (http://genome.ucsc.edu/). In total, 30
assays targeting 10 different regions on 5 chromosomes
were designed using PrimerBlast (NCBI). Ampliﬁcation
efﬁciencies were determined with a dilution series of
gDNA (50–5000 haploid genome copies). PCR products
were analyzed for purity by recording melting curves and
by capillary micro-electrophoresis (MultiNA, Shimadzu),
leading to the selection of ﬁve assays for limit of detection
(LOD) and limit of quantiﬁcation (LOQ) determination.
LOD and LOQ determination of ValidPrime assays
Five assays were selected for determination of LOD and
LOQ using eight concentrations (0, 1, 2, 4, 8, 16, 32, 64
copies) in the presence of 50ng/ml carrier yeast tRNA
(Roche Molecular Biochemicals). Sequence information
for the two best candidates, in terms of sensitivity and spe-
ciﬁcity, is provided in Supplementary Table S1. Except
when stated otherwise, mVPA1 was used as the VPA.
GOI assay design and validation
Non-commercial GOI assays were either taken from pre-
viously published studies (5,8,9) or designed with the
Primer-BLAST utility at NCBI. Sequences are reported
in Supplementary Table S1. Speciﬁcity was evaluated by
BLAST (mouse RefSeq database) during design and by in
silico PCR (UCSC Genome Browser). Ampliﬁcation
efﬁciencies were evaluated in the BioMark system on di-
lutions series of both cDNA and gDNA.
Exogenous gDNA spiking experiments
Quantities ranging from 50 to 5000 haploid genome
copies (corresponding to 0.15–15ng gDNA) or water
were added to 20ng (StepOnePlus) or 6.5ng (BioMark)
cDNA. Non-spiked samples had low, but detectable
gDNA levels. For the BioMark runs, the gDNA was
added prior to the pre-ampliﬁcation step. Genome
copy number calculations were based on the NCBI m37
assembly of the C57Bl/6 mouse genome (2716965481bp)
assuming an average molecular weight of 660g/mol/bp.
The mass of a haploid mouse genome was thus estimated
to be 2.98pg.
Data analysis and statistics
CqDNA, CqRNA and %DNA were calculated using the
gh-validprime software (https://code.google.com/p/gh-
validprime). The GenEx software (v.5.3, www.multiD.se)
was used for one-way ANOVA analysis and to calculate
LOD. Data are presented as mean±SD.
RESULTS
The ValidPrime method
We developed ValidPrime to estimate and correct for
gDNA contribution in RT(+)–qPCR measurements in a
more reliable manner than that afforded by RT( )
controls. We refer to the signal measured in an RT(+)–
qPCR as CqNA (NA : Nucleic Acids) [Equation (1)],
indicating contributions from RNA (CqRNA) as well as
gDNA (CqDNA) as shown in Equation (2), expressed in
relative quantities.
CqRT+ ¼ CqNA ð1Þ
2 CqNA ¼ 2 CqRNA+2  CqDNA ð2Þ
Traditionally, determination of the RNA component
using RT( ) controls would be achieved using Equation
(3). However, as detailed in the introduction, low repro-
ducibility and other factors detract from the accuracy of
this approach. We propose that Equation (4), derived in
Supplementary Figure S1A, provides an accurate solution
provided that CqDNA is estimated using ValidPrime,
Equation (5), in which GOI refers to any transcribed
‘GOI’, including reference genes, studied in a RT–qPCR
experiment. CqRNA and CqDNA refer to the signal contri-
bution derived from RNA (cDNA) and DNA (gDNA),
respectively, in a RT+sample.
CqRNA ¼ log2ð2 CqRT+   2 CqRT Þð 3Þ
CqRNA ¼ log2ð2 CqNA   2 CqDNAÞð 4Þ
CqDNA ¼ CqVPA
Sample+CqGOI
gDNA   CqVPA
gDNA ð5Þ
For the determination of CqDNA [Equation (5)], the
gDNA contamination level in a RT(+) sample (referred
to as ‘Sample’) is measured with a gDNA-speciﬁc
ValidPrime assay (VPA) (CqVPA
sample). The VPA targets a
non-transcribed locus present in one copy per normal
haploid genome. However, since the gDNA sensitivity
can be highly variable between GOI assays, the capacity
of the GOI assay to amplify gDNA is compared with that
of the VPA. In ValidPrime, this difference is tested on
puriﬁed gDNA, yielding the delta Cq component in
Equation (5) (CqGOI
gDNA–CqVPA
gDNA). Despite a formulaic
resemblance to the   Ct equation developed by Livak
and Schmittgen (10), these calculations are distinct
(Supplementary Figure S1B).
Figure 1 depicts a typical grid of qPCR data including
the required controls for ValidPrime estimation of CqDNA
and the subsequent correction of CqNA into CqRNA. Apart
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VPA has been added among the assays. In addition to
samples 1–3, which correspond to any RT+ samples
in qPCR study, one or several gDNA samples are added
in the experimental design. The equations under the grid
exemplify the calculations for GOI 1 in Sample 1. The
gDNA contribution can also be expressed as a percentage
of relative quantities [Equation (6)].
%DNA ¼
2 CqDNA
2 CqNA

  100 ð6Þ
Assay validation
In order to determine the accuracy of the ValidPrime
method, we ﬁrst designed and characterized candidate
VPAs. Among 30 candidates from 10 different regions
on ﬁve chromosomes, 26 ampliﬁed gDNA with efﬁciencies
between 90 and 110%. Among the tested assays, mVPA1
(amplifying an 87-bp sequence in the qB region of
chromosome 1) and mVPA5 (amplifying an 87-bp
sequence in the qF region of chromosome 5) had the
best characteristics in terms of sensitivity and speciﬁcity.
LOD was 3.2 copies for mVPA1 (GenEx; Cut-off Cq 37;
95% CI; mean of two determinations) and 3.7 copies for
mVPA5 (GenEx; Cut-off Cq 37; 95% CI) and the LOQ
(SD<45%) was 4 copies for both assays (Supplementary
Figure S2). In four out of eight NTC reactions, a signal
(Cq 38.1±0.9) was detected with the mVPA5 assay,
indicating formation of primer–dimers. However, the
primer–dimer product was never observed in samples con-
taining gDNA, as evaluated by melting curve analyses and
by capillary micro-electrophoresis (MultiNA, Shimadzu).
Efﬁciency analysis for GOI assays was performed in the
BioMark system. No ampliﬁcation was observed in the
NTC controls, except for Sprr2f (Cq 28.6), which was
10 cycles above the Cq measured in the sample with the
lowest Sprr2f expression (Cq 18.5) and thus, far more than
the proposed accepted minimal difference of ﬁve cycles
between NTC and RT(+) sample (11,12). The generally
low Cq values obtained with the BioMark system are ex-
plained by the 14-cycle pre-ampliﬁcation step used in this
protocol. The ampliﬁcation efﬁciency was similar between
assays as measured with a cDNA dilution series
(95.5±6.1%; mean R
2: 0.9932) and a gDNA dilution
series for gDNA-sensitive assays (100.4±7.7%; mean
R
2 : 0.9962) (data not shown). All RNA samples used in
the study had A260/A280 ratios between 1.9 and 2.0
(mean: 1.97); A260/A230 between 1.5 and 2.5 (mean:
2.13) and A260/A270 above 1.17 (mean: 1.23), where the
latter tests for phenol contamination.
Equivalence between CqDNA estimated with ValidPrime
and RT( ) controls
We next veriﬁed that the CqDNA values calculated with
ValidPrime agree with those measured directly in
RT( )–qPCRs. Since a direct comparison is difﬁcult,
due to the poor reproducibility of RT( ) controls
(see above), the following test was performed: RT(+)
and RT( ) samples from two different tissues were
spiked with 0.30ng of gDNA (approximately 100
haploid genome copies) and measured using three
gDNA-sensitive GOI assays. The data in Figure 2 are
ratios of relative quantities (RQ) between either the total
signal (CqNA) in RT(+) reactions or the corresponding
CqDNA calculated by ValidPrime over the RQ in RT( )
reactions. As shown, tissue-dependent differences in the
expression levels of the three target genes were observed
[from 1.8- to 27-fold compared with RT( ) samples].
Independent of the expression level, the estimation by
ValidPrime of the gDNA-derived signal levels (CqDNA)
in RT(+) samples was in excellent agreement with the
data from RT( ) samples, with the ratio of the relative
quantities (1.20±0.29) close to the theoretically expected
value of 1.
Calculation of CqRNA in RT(+) samples through the
correction of signals derived from exogenously added
gDNA
Given the good correlation between ValidPrime estima-
tion of CqDNA and RT( ) measurements, we next tested
the accuracy of the calculation of the RNA-derived com-
ponent CqRNA in RT(+) samples using Equation (4). In a
ﬁrst set of experiments, different amounts of gDNA were
Figure 1. ValidPrime: principles and exemplifying equations.
ValidPrime uses the annotation CqNA for the signal measured in a
(RT+) qPCR sample, to which both Nucleic Acids, RNA and DNA
contribute, corresponding to CqRNA and CqDNA [Equation (2)]. The
grid shows an example of an experimental design with 3 RT+
samples and 3 GOI assays, plus the controls required for the
ValidPrime estimation of CqDNA and the subsequent correction of
CqNA to obtain CqRNA. The term GOI is used in ValidPrime for
both target transcripts and reference genes, since the calculations are
independent of the gene type. The VPA column contains the data
obtained with the VPA and the gDNA row contains measurements
using puriﬁed gDNA as a sample. The equations under the grid illus-
trate the determination of CqDNA, CqRNA and %DNA for GOI 1 in
sample 1 according to the color code in the grid.
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endogenous gDNA levels. All 32 GOI assays were
gDNA-sensitive (Supplementary Table S1) and had
gDNA ampliﬁcation efﬁciencies similar to the VPA (i.e.
passed the ValidPrime high conﬁdence criteria detailed in
Supplementary Figure S3). Both the traditional
StepOnePlus microtiter plate-based qPCR (Figure 3A)
and the microﬂuidic BioMark system (7) (Figure 3B)
were used to collect raw data (CqNA) as input for
ValidPrime estimations of the RNA-derived signal
(CqRNA). Samples were grouped according to the level
of DNA contribution. Using ValidPrime, we could accur-
ately estimate the RNA-derived signal (CqRNA) even in
samples with elevated gDNA-derived signals. However,
the correction was less precise when the gDNA back-
ground exceeded 60% of the total signal. The demonstra-
tion that with ValidPrime we can identify and correct for
signals derived from exogenous DNA in experimental
RT–qPCR samples, using two different qPCR platforms,
was ﬁrst step toward a ‘proof-of-principle’. The correction
is virtually independent of gene copy number since it
works well both for GOI assays targeting one single
locus and for genes with multiple pseudogenes
(Supplementary Figure S4).
Correction of signals derived from endogenous gDNA
In order to evaluate the capacity of ValidPrime to correct
for endogenous gDNA present in typical RNA prepar-
ations, a different strategy was applied. We used a
gDNA-sensitive and a gDNA-insensitive assay for each
GOI, with comparable ampliﬁcation efﬁciencies. Three
genes (Il1b, Serpine1 and Chi3l3) expressed in mouse
macrophages were chosen as targets. Using the BioMark
system, qPCR data were collected from 81 RNA
preparations and the ValidPrime correction was applied.
Despite identical overall gDNA content, the impact of the
gDNA on the total signal obtained with the
gDNA-sensitive assays differed considerably between the
three genes. When the impact was limited (i.e. low
%DNA), as in the case for Il1b, the effect of the
ValidPrime correction was modest (Supplementary
Figure S5). With increasing %DNA, as observed for
Serpine1 and Chi3l3 (Figure 4A), the result of the correc-
tion becomes clearer, even in log2 scale (Figure 4B).
Theoretically, given identical ampliﬁcation efﬁciencies
for the two assays and the absence of gDNA ampliﬁca-
tion, the CqNA data in the scatter plots in Figure 4B
should fall on a straight line with a slope of 1. The
presence of gDNA will contribute to the signal measured
with gDNA sensitive assays (x-axis) and the uncorrected
CqNA data will therefore produce a slope >1. Even though
the impact of the correction differs for the three genes, the
CqRNA values estimated using ValidPrime restore linear-
ity, especially for samples with a DNA contribution
<60% (summarized in Figure 4C).
These data demonstrate that using ValidPrime, efﬁcient
correction of RT–qPCR data for the presence of endogen-
ous gDNA is possible, as long as the DNA contribution to
the total signal is <60%.
DISCUSSION
Since its invention in the early/mid 1990s (13,14), qPCR
has undergone considerable methodological and techno-
logical advances (15). However, despite its direct impact
on qPCR results, no alternative to RT( ) controls has, to
our knowledge, been proposed to assess gDNA-derived
contributions to the signals in RT–qPCR.
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-Cq(RT+)/2
-Cq(RT )) between
either the total signal (NA) measured in spiked RT(+) reactions (dark bars) or the gDNA signal (DNA) estimated by ValidPrime (VP) from RT(+)
reactions (light bars) compared to the signal in RT( ) reactions. A quantity of 20ng of cDNA from adipose tissue (hatched bars) or from kidney,
were spiked with 0.30ng gDNA to decrease the variability due to stochastic ampliﬁcation observed in RT( ) reactions. Independently of the
expression level of the three genes studied in RT(+) samples, the estimations by ValidPrime of the gDNA-derived signals in RT(+) were very
similar to the signals measured in RT( ) reactions, as the ratio was close to 1 (illustrated by the red dashed line; mean 1.20±0.29). Data are
mean±SD from two experiments in duplicate on the StepOnePlus.
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controls to test for the presence of gDNA in samples.
It is superior to RT( ) controls not only because of a
higher accuracy, but also because fewer control reactions
are required, eliminating the need for additional test reac-
tions in the RT step. While the traditional approach for a
study based on m samples and n genes requires m reverse
transcription control reactions (RT ) and m n extra
qPCRs, ValidPrime only requires m+n+1 control
qPCRs and no RT( ) reactions (Table 1). As an
example, in a BioMark 96.96 Dynamic Array experiment,
ValidPrime reduces the number of controls by >95%.
ValidPrime is also the ﬁrst method that proposes to
correct for qPCR signals originating from contaminating
gDNA. It is possible that the lack of accuracy and low
reproducibility generally observed in RT( ) reactions has
previously restrained the development of a correction-
based model similar to that proposed in Equation (3).
The present study includes data obtained with cDNA
from ﬁve different mouse tissues analyzed with two
qPCR instrument platforms, providing support for the
general validity of ValidPrime.
It is important not to confuse gDNA contamination
levels with the actual contribution of gDNA to the total
signal, herein expressed as %DNA [Equation (6)]. Indeed,
we did not observe any correlation between gDNA levels
(as estimated by qPCR with the VPA) and the total signal
(CqNA) measured in RT(+) qPCR reactions with GOI
assays (Supplementary Figure S6). However, as evidenced
from the data shown in Figure 4A and Supplementary
Figure S5A, there is a clear positive correlation between
%DNA and CqNA with the gDNA sensitive assay, which
demonstrates the increased impact of contaminating
gDNA in samples with low GOI expression levels.
The primer design strategy also strongly inﬂuences
the impact of gDNA on the qPCR signal. Given
the multi-exonic nature of most eukaryotic genes (16), it
is conceivable that gDNA-insensitive assays can be
designed for most targets in vertebrates. Regardless of
the primer design strategy, the inability of a GOI assay
to amplify gDNA needs to be validated experimentally.
ValidPrime offers this possibility. However, for certain
targets it is impossible to design transcript-speciﬁc
assays. This can be due to either the presence of intronless
pseudogenes or the absence of introns in single-exon
genes. In order to assure a good accuracy for the
ValidPrime correction, these gDNA sensitive assays
should behave similarly to VPA against gDNA. In
analogy with the comparative Ct method (or   Ct
method) (10), in which similar ampliﬁcation efﬁciencies
for the GOI and reference gene assays are presumed, es-
timation of CqRNA in ValidPrime assumes similar
efﬁciencies for the GOI and gDNA assays.
When validated according to the Minimal Information
for publication of Quantitative real-time PCR
Experiments (MIQE) guidelines (17), gDNA-sensitive
assays are in general perfectly compatible with
ValidPrime. Nevertheless, when using a GOI assay for
the ﬁrst time with ValidPrime, and especially when Cq
adjustment is requested, we recommend the inclusion of
a gDNA dilution series with concentrations covering at
least three log10 (e.g. 5–5000 haploid genomic copies).
Consistent relation to VPA across the dilution series indi-
cates similar ampliﬁcation efﬁciencies of the two assays,
which sanctions Cq correction with high conﬁdence
(Supplementary Figure S3). For VPAs, as well as
for high conﬁdence GOI assays, we generally observed
perfectly linear ampliﬁcations from 5 to 10000 hap-
loid genomic copies (corresponding to 0.015–30ng)
(Supplementary Figures S2 and S3). Even though it is
possible that higher gDNA concentrations (i.e. >30ng
per reaction) could inﬂuence qPCR ampliﬁcation
efﬁciencies (18), such gDNA contamination levels are
rarely, if ever, encountered in RT–qPCR experiments.
Furthermore, we did not observe any differences in the
VPA ampliﬁcation between samples with puriﬁed gDNA
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with 19 assays on a BioMark (Fluidigm) using mVPA1 (B). All assays passed the high conﬁdence ValidPrime criteria (Supplementary Figure S3).
Data are presented as the mean±SD, with (n) designating the number of samples in each group. cDNAs were from mouse kidney or liver for the
StepOnePlus studies and mouse uterus for the BioMark study.
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(Supplementary Table S2).
Even though we consistently observed very low variabil-
ity between replicates in VPA-gDNA ampliﬁcations
over a wide range of initial gDNA concentrations
(Supplementary Figure S2 and Supplementary Table S2),
it is advisable to use 1–10ng gDNA (i.e. &300–3000
haploid genome copies) per qPCR, when only one
gDNA concentration is included in the design. This
range favors reliable and distinct gDNA ampliﬁcation
with the VPA and the ‘high conﬁdence’ gDNA-sensitive
GOI assays. It also increases the conﬁdence when verify-
ing the absence of gDNA ampliﬁcation with GOI assays
that are presumed to be ‘gDNA-insensitive’.
In this study, we used a maximal 0.3 SD for the  Cq
between VPA and GOI gDNA ampliﬁcations as criterion
for high conﬁdence gDNA-sensitive GOI assays.
Alternatively, an efﬁciency (E) based criterion can be
0
20
40
60
80
100
51 01 5 2 0
CqNA (gDNA sensitive assay)
%
D
N
A
0
20
40
60
80
100
51 0 1 52 0
CqNA (gDNA sensitive assay)
%
D
N
A
Serpine1 Chi3l3 A
Mean: 17.0%
Median: 9.7%
Mean: 41.8%
Median: 37.9%
Data type Correction Filter (%DNA) Slope R
2 n
CqNA No None 1.100 0.979 81
CqRNA Yes None 0.881 0.976 81
CqRNA Yes >60 0.940 0.988 77
Serpine1
Data type Correction Filter (%DNA)  Slope R
2 n
CqNA No None 1.40 0.549 81
CqNA No >90 1.13 0.537 74
CqRNA Yes >90 1.03 0.801 74
CqRNA Yes >70 0.97 0.834 68
CqRNA Yes >60 0.97 0.946 63
Chi3l3
C
5
10
15
20
51 0 1 5 2 0
Cq (gDNA sensitive assay)
C
q
 
(
g
D
N
A
 
i
n
s
e
n
s
i
t
i
v
e
 
a
s
s
a
y
)
5
10
15
20
51 01 5 2 0
Cq (gDNA sensitive assay)
C
q
 
(
g
D
N
A
 
i
n
s
e
n
s
i
t
i
v
e
 
a
s
s
a
y
)
CqNA (VP-)
CqRNA (VP+)(<60%DNA)
CqRNA (VP+)(60-90%DNA)
B
Figure 4. Correction of endogenous gDNA with ValidPrime. Comparison of results obtained with two assays targeting Serpine1 (left) or Chi3l3
(right) in cDNA prepared from mouse peritoneal macrophages and measured in the BioMark qPCR system. The ‘gDNA-sensitive’ assays amplify
both gDNA and cDNA, while the ‘gDNA-insensitive’ assays only recognize the transcript. (A) Scatter plots showing the correlation between the
%DNA [as deﬁned in Equation (6)] and CqNA data obtained with the gDNA-sensitive assays in each of 81 independent RNA preparations (means of
duplicates). The positive correlation between %DNA and Cq illustrates the increasing impact of the gDNA contamination with decreasing total
signal. Mean and median values refer to %DNA levels. (B) CqNA data measured with the gDNA-insensitive assays plotted against the corresponding
CqNA data (dark blue) or ValidPrime-estimated CqRNA (light blue and orange), obtained with the gDNA-sensitive assays. Samples with a DNA
contribution of 60–90 % are shown in orange and those with <60% in light blue. (C) Tables summarizing the effect of ValidPrime correction and
data ﬁltering on the slope and the coefﬁcient of determination (R
2).
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were obtained when a maximal difference of 0.15 in
E (deﬁned as 10
-1/slope-1) was used as inclusion criterion
(data not shown). If a gDNA-sensitive GOI assay has a
suboptimal, but conﬁdently estimated E and cannot be
replaced with a better assay, Equation (7) (19), or equiva-
lent (20), can be used to correct the CqNA. Procedures for
conﬁdent determination of ampliﬁcation efﬁciencies are
described elsewhere (21).
CqNAnew ¼ CqNAold
logð1+EÞ
logð2Þ

ð7Þ
Coherency of PCR product melting curve proﬁles
from cDNA and gDNA samples should also be con-
sidered prior to CqRNA calculations. If a GOI assay
generates gDNA-speciﬁc products that are not observed
in cDNA samples, CqRNA adjustment of CqNA will not be
reliable and is not recommended or even needed.
Electrophoresis-based analysis of PCR-products is an al-
ternative informative tool to verify that the same products
are formed from cDNA and gDNA templates.
Caution should also be taken if differences in ploidy are
expected, such as in cancer biopsies, since the number of
VPA and GOI targets per cell could vary between samples.
However, homogenous populations of aneuploid samples
can be analyzed with ValidPrime, such as cancer cell lines,
given that the VPA and GOI target loci are each present at
least in one copy per cell.
To make ValidPrime readily available, we have
developed a software application (gh-validprime) (H. L.
and J. I., manuscript in preparation), that is free of charge
for academic use. ValidPrime CqRNAcalculation is also
available within the data pre-processing workﬂow of the
GenEx software (version 5.3, www.multid.se). The
gh-validprime software assigns grades to assays/samples
based on the impact of the genomic background
(Supplementary Figure S7). The gDNA-insensitive
assays are classiﬁed as A+. Other assays are attributed
the grades A, B, C and F, where the assignment is
sample-dependent. While A (<3 %DNA) does not
require correction, B and C samples (3–25 and 25–60
%DNA, respectively) are corrected, provided the assays
pass the high conﬁdence criteria. If gDNA contribution
exceeds 60%, correction is not recommended. RT+
samples with gDNA concentrations below the limit of de-
tection, in which the VPA fail to generate a signal, are
attributed the grade A*. The default output from the
ValidPrime software is either CqNA (for A+ assays, A*
and A samples), CqRNA (for B and C samples) or
‘HIGHDNA’ for F samples. The output data are ready
for further pre-processing, such as normalization against
reference genes. The general ValidPrime workﬂow is
summarized in Figure 5. The gDNA sensitivity and con-
ﬁdence evaluation of GOI assays can be performed inde-
pendently, as outlined in Figure 5A, or together with
RT(+) samples, which facilitates the speciﬁcity assessment.
Figure 5B illustrates the ﬂowchart for previously validated
GOI assays.
The ValidPrime source code is available through the
gh-validprime project at https://code.google.com/p/gh-
validprime. This software depends on the Qt framework
(http://qt.nokia.com) and the GeneHuggers library
(https://code.google.com/p/genehuggers). A windows in-
staller and test ﬁles are available at http://code.google
.com/p/gh-validprime/downloads/list.
ValidPrime assays targeting different species (including
human, mouse and a general vertebrate) have been de-
veloped by the TATAA Biocenter (www.tataa.com).
CONCLUSION
ValidPrime provides, for the ﬁrst time, the opportunity to
correct reliably for gDNA background in qPCR.
Correction is possible for any GOI assay that consistently
ampliﬁes gDNA, given that the DNA contribution does
not exceed 60% of the signal. ValidPrime is superior to
traditional RT( ) controls because of its higher accuracy
and the lower number of controls required, which leads to
a substantial cost savings.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1 and 2, Supplementary Figures
1–7 and Supplementary References [1,10,17,22–25].
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Table 1. ValidPrime reduces the number of required control reactions
in RT–qPCR
No. of controls Assays (n)
1 1 02 44 89 6
Samples (m)
12 3 11 12 25 26 49 50 97 98
10 20 12 110 21 250 35 490 59 970 107
24 48 26 264 35 600 49 1176 73 2328 121
48 96 50 528 59 1200 73 2352 97 4656 145
96 192 98 1056 107 2400 121 4704 145 9312 193
The roman values indicates Traditional RT  strategy: (m n)+m and
the bold values indicates ValidPrime: (m+n+1). ValidPrime replaces
the need to perform RT( ) controls for all RT(+) reactions and
reduces substantially the number of controls compared to a conven-
tional set up. In an expression proﬁling experiment based on m samples
and n assays, the RT( ) approach requires m RT( ) reactions followed
by m n qPCR controls, whereas ValidPrime only requires m+n+1
controls. The numbers in the table are based on single measurements
for both approaches. Even when p gDNA samples/concentrations are
included in the experimental setup using ValidPrime, the number of
control reactions [m+(p n)+p] is still largely inferior to the RT( )
approach.
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Figure 5. ValidPrime ﬂowchart. ValidPrime GOI assay validation. ValidPrime can be used as a reliable, cost-efﬁcient alternative to RT( ) controls
to survey gDNA background in RT–qPCR, and as a tool to determine the RNA-derived signal (CqRNA) in RT(+)–qPCR reactions. To optimize its
accuracy when CqRNA calculation is desired, validation of GOI assays in gDNA samples is recommended, as outlined in (A). Asterisks indicates the
efﬁciency evaluation and melting curve/electrophoresis-based analysis. This includes an evaluation of the gDNA sensitivity of GOI assays using
dilution series with gDNA samples spanning at least three log10 in copy number. GOI assays that do not amplify gDNA are attributed the grade A+.
The ampliﬁcation of gDNA by high-conﬁdence assays should be speciﬁc and with an efﬁciency similar to that of the VPA (see ‘Discussion’ section
and Supplementary Figure S3). For GOI assays with suboptimal, but conﬁdently determined (17,21) efﬁciency, Equation (7) could be applied to
adjust CqNAdata. To optimize speciﬁcity, there should also be consistency between the melting curves of PCR products in gDNA and cDNA
samples. (B) CqRNA calculation with ValidPrime-validated GOI assays. High conﬁdence and A+ assays can be used with less gDNA samples for
CqRNA determination. It is recommended to conﬁrm the absence of gDNA ampliﬁcation at least once for A+ assays. Samples that do not contain
sufﬁcient gDNA to generate a signal with the VPA are attributed A*. As for gDNA insensitive A+assays, CqRNA equals CqNA (i.e. output=input)
in A* samples, since the DNA-derived signal is negligible [see Equations (2 and 4)]. For gDNA-sensitive GOI assays, CqRNA is calculated by a
CqDNA-based correction of CqNA using Equations (4 and 5). To minimize the risk of jeopardizing the accuracy of the CqRNA estimation, it is not
advisable to perform correction on samples where the DNA-derived signal exceeds 60%. The calculations are facilitated using the ValidPrime
software. Details on additional assay/sample grading and data output formats employed by the software are provided in Supplementary Figure S7.
The CqRNA output data can be used for downstream data processing, such as normalization against reference genes.
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